{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:22:53Z","timestamp":1795141373333,"version":"4.10.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81730008,81770201"],"award-info":[{"award-number":["81730008,81770201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Project of Science and Technology Department of Zhejiang Province"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for hematologic malignancies, however, response rates and associated immune-related adverse effects widely vary among patients. Here we show, by comparing diversity and composition of the gut microbiome during different CAR-T therapeutic phases in the clinical trial ChiCTR1800017404, that the gut flora characteristically differs among patients and according to treatment stages, and might also reflect patient response to therapy in relapsed\/refractory multiple myeloma (MM;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200943), acute lympholastic leukemia (ALL;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200923) and non-Hodgkin lymphoma (NHL;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912). We observe significant temporal differences in diversity and abundance of Bifidobacterium, Prevotella, Sutterella, and Collinsella between MM patients in complete remission (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200924) and those in partial remission (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911). Furthermore, we find that patients with severe cytokine release syndrome present with higher abundance of Bifidobacterium, Leuconostoc, Stenotrophomonas, and Staphylococcus, which is reproducible in an independent cohort of 38 MM patients. This study has important implications for understanding the biological role of the microbiome in CAR-T treatment responsiveness of hematologic malignancy patients, and may guide therapeutic intervention to increase efficacy. The success rate of CAR-T cell therapy is high in blood cancers, yet individual patient characteristics might reduce therapeutic benefit. Here we show that therapeutic response in MM, ALL and NHL, and occurrence of severe cytokine release syndrome in multiple myeloma are associated with specific gut microbiome alterations.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-32960-3","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T09:29:02Z","timestamp":1662715742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":144,"title":["CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies"],"prefix":"10.1038","volume":"13","author":[{"given":"Yongxian","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9882-7377","authenticated-orcid":false,"given":"Jingjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimin","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7572-309X","authenticated-orcid":false,"given":"Alex H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0696-4401","authenticated-orcid":false,"given":"Marcel R. M.","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming D.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2723-1621","authenticated-orcid":false,"given":"He","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"32960_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.addr.2017.06.010","volume":"114","author":"R Stephenson","year":"2017","unstructured":"Stephenson, R. & Singh, A. Drug discovery and therapeutic delivery for the treatment of B and T cell tumors. Adv. Drug Deliv. Rev. 114, 285\u2013300 (2017).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"32960_CR2","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann, T. M. et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24, 3121\u20133127 (2006).","journal-title":"J. Clin. Oncol."},{"key":"32960_CR3","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"ME Goebeler","year":"2016","unstructured":"Goebeler, M. E. et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed\/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. J. Clin. Oncol. 34, 1104\u20131111 (2016).","journal-title":"J. Clin. Oncol."},{"key":"32960_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","volume":"373","author":"HM Lokhorst","year":"2015","unstructured":"Lokhorst, H. M. et al. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. N. Engl. J. Med. 373, 1207\u20131219 (2015).","journal-title":"N. Engl. J. Med"},{"key":"32960_CR5","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1182\/asheducation-2017.1.508","volume":"2017","author":"P Sonneveld","year":"2017","unstructured":"Sonneveld, P. Management of multiple myeloma in the relapsed\/refractory patient. Hematol. Am. Soc. Hematol. Educ. Program 2017, 508\u2013517 (2017).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"32960_CR6","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","volume":"120","author":"N Gokbuget","year":"2012","unstructured":"Gokbuget, N. et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120, 2032\u20132041 (2012).","journal-title":"Blood"},{"key":"32960_CR7","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1002\/cncr.25354","volume":"116","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian, H. M. et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116, 5568\u20135574 (2010).","journal-title":"Cancer"},{"key":"32960_CR8","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump, M. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130, 1800\u20131808 (2017).","journal-title":"Blood"},{"key":"32960_CR9","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar, S. K. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 26, 149\u2013157 (2012).","journal-title":"Leukemia"},{"key":"32960_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med"},{"key":"32960_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"32960_CR12","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"32960_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"WH Zhao","year":"2018","unstructured":"Zhao, W. H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11, 141 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"32960_CR14","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","volume":"380","author":"N Raje","year":"2019","unstructured":"Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380, 1726\u20131737 (2019).","journal-title":"N. Engl. J. Med."},{"key":"32960_CR15","doi-asserted-by":"publisher","first-page":"2267-+","DOI":"10.1200\/JCO.2018.77.8084","volume":"36","author":"JN Brudno","year":"2018","unstructured":"Brudno, J. N. et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267-+ (2018).","journal-title":"J. Clin. Oncol."},{"key":"32960_CR16","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","volume":"116","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116, 9543\u20139551 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"32960_CR17","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","volume":"128","author":"SA Ali","year":"2016","unstructured":"Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688\u20131700 (2016).","journal-title":"Blood"},{"key":"32960_CR18","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.aar6918","volume":"359","author":"L Zitvogel","year":"2018","unstructured":"Zitvogel, L., Ma, Y., Raoult, D., Kroemer, G. & Gajewski, T. F. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science 359, 1366\u20131370 (2018).","journal-title":"Science"},{"key":"32960_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97\u2013103 (2018).","journal-title":"Science"},{"key":"32960_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-018-0592-6","volume":"11","author":"M Yi","year":"2018","unstructured":"Yi, M. et al. Gut microbiome modulates efficacy of immune checkpoint inhibitors. J. Hematol. Oncol. 11, 47 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"32960_CR21","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","volume":"350","author":"M Vetizou","year":"2015","unstructured":"Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079\u20131084 (2015).","journal-title":"Science"},{"key":"32960_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/blood-2016-09-691394","volume":"129","author":"A Staffas","year":"2017","unstructured":"Staffas, A., Burgos da Silva, M. & van den Brink, M. R. M. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood 129, 927\u2013933 (2017). Blood 129, 2204 (2017).","journal-title":"Blood"},{"key":"32960_CR23","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.bbmt.2015.04.016","volume":"21","author":"RR Jenq","year":"2015","unstructured":"Jenq, R. R. et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol. Blood Marrow Transplant. 21, 1373\u20131383 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"32960_CR24","doi-asserted-by":"publisher","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","volume":"27","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. Risk factors associated with durable progression-free survival in patients with relapsed or refractory multiple myeloma treated with anti-BCMA CAR T-cell therapy. Clin. Cancer Res. 27, 6384\u20136392 (2021).","journal-title":"Clin. Cancer Res."},{"key":"32960_CR25","doi-asserted-by":"crossref","unstructured":"Segata, N. et al. Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60 (2011).","DOI":"10.1186\/gb-2011-12-6-r60"},{"key":"32960_CR26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.cmet.2020.06.005","volume":"32","author":"TG Oh","year":"2020","unstructured":"Oh, T. G. et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab. 32, 878\u2013888.e876 (2020).","journal-title":"Cell Metab."},{"key":"32960_CR27","doi-asserted-by":"publisher","first-page":"739-+","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739-+ (2018).","journal-title":"Nat. Med."},{"key":"32960_CR28","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"32960_CR29","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. & Kochenderfer, J. N. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127, 3321\u20133330 (2016).","journal-title":"Blood"},{"key":"32960_CR30","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fpsyg.2017.00456","volume":"8","author":"JZ Bakdash","year":"2017","unstructured":"Bakdash, J. Z. & Marusich, L. R. Repeated measures correlation. Front. Psychol. 8, 456 (2017).","journal-title":"Front. Psychol."},{"key":"32960_CR31","doi-asserted-by":"crossref","unstructured":"Peters, B. A. et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med. 11, 61 (2019).","DOI":"10.1186\/s13073-019-0672-4"},{"key":"32960_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104\u2013108 (2018).","journal-title":"Science"},{"key":"32960_CR33","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.cell.2017.01.022","volume":"168","author":"N Geva-Zatorsky","year":"2017","unstructured":"Geva-Zatorsky, N. et al. Mining the human gut microbiota for immunomodulatory organisms. Cell 168, 928\u2013943.e11 (2017).","journal-title":"Cell"},{"key":"32960_CR34","unstructured":"Smith, M. et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat. Med. 28, 713\u2013723 (2022)."},{"key":"32960_CR35","doi-asserted-by":"crossref","unstructured":"Botticelli, A. et al. Changes of microbiome profile during nivolumab treatment in NSCLC patients. J. Clin. Oncol. 36, e15020-e15020 (2018).","DOI":"10.1200\/JCO.2018.36.15_suppl.e15020"},{"key":"32960_CR36","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1016\/j.cell.2016.11.046","volume":"167","author":"M Schirmer","year":"2016","unstructured":"Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1897 (2016).","journal-title":"Cell"},{"key":"32960_CR37","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1080\/10408398.2011.619671","volume":"54","author":"R Ashraf","year":"2014","unstructured":"Ashraf, R. & Shah, N. P. Immune system stimulation by probiotic microorganisms. Crit. Rev. Food Sci. 54, 938\u2013956 (2014).","journal-title":"Crit. Rev. Food Sci."},{"key":"32960_CR38","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1067\/mai.2002.124894","volume":"109","author":"F He","year":"2002","unstructured":"He, F. et al. Intestinal Bifidobacterium species induce varying cytokine production. J. Allergy Clin. Immunol. 109, 1035\u20131036 (2002).","journal-title":"J. Allergy Clin. Immunol."},{"key":"32960_CR39","doi-asserted-by":"publisher","first-page":"572","DOI":"10.4049\/jimmunol.1601247","volume":"198","author":"E Blacher","year":"2017","unstructured":"Blacher, E., Levy, M., Tatirovsky, E. & Elinav, E. Microbiome-modulated metabolites at the interface of host immunity. J. Immunol. 198, 572\u2013580 (2017).","journal-title":"J. Immunol."},{"key":"32960_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1471-2180-12-68","volume":"12","author":"G Matera","year":"2012","unstructured":"Matera, G. et al. Procalcitonin neutralizes bacterial LPS and reduces LPS-induced cytokine release in human peripheral blood mononuclear cells. BMC Microbiol. 12, 68 (2012).","journal-title":"BMC Microbiol."},{"key":"32960_CR41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1165\/rcmb.2011-0289OC","volume":"46","author":"MH Wong","year":"2012","unstructured":"Wong, M. H., Chapin, O. C. & Johnson, M. D. LPS-stimulated cytokine production in type I cells is modulated by the renin-angiotensin system. Am. J. Resp. Cell Mol. Biol. 46, 641\u2013650 (2012).","journal-title":"Am. J. Resp. Cell Mol. Biol."},{"key":"32960_CR42","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00018-003-3019-6","volume":"60","author":"R Dziarski","year":"2003","unstructured":"Dziarski, R. Recognition of bacterial peptidoglycan by the innate immune system. Cell Mol. Life Sci. 60, 1793\u20131804 (2003).","journal-title":"Cell Mol. Life Sci."},{"key":"32960_CR43","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1017\/S000711450769936X","volume":"98","author":"P Li","year":"2007","unstructured":"Li, P., Yin, Y. L., Li, D., Kim, S. W. & Wu, G. Y. Amino acids and immune function. Br. J. Nutr. 98, 237\u2013252 (2007).","journal-title":"Br. J. Nutr."},{"key":"32960_CR44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12253-014-9860-0","volume":"21","author":"AK Sikalidis","year":"2015","unstructured":"Sikalidis, A. K. Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer? Pathol. Oncol. Res. 21, 9\u201317 (2015).","journal-title":"Pathol. Oncol. Res."},{"key":"32960_CR45","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1600-065X.2010.00915.x","volume":"236","author":"U Grohmann","year":"2010","unstructured":"Grohmann, U. & Bronte, V. Control of immune response by amino acid metabolism. Immunol. Rev. 236, 243\u2013264 (2010).","journal-title":"Immunol. Rev."},{"key":"32960_CR46","doi-asserted-by":"crossref","unstructured":"Xiao, N. et al. Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. Nat. Commun. 12, 1618 (2021).","DOI":"10.1038\/s41467-021-21907-9"},{"key":"32960_CR47","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"32960_CR48","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"key":"32960_CR49","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","volume":"23","author":"YX Hu","year":"2017","unstructured":"Hu, Y. X. et al. Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in chinese patients with relapsed\/refractory acute lymphocytic leukemia. Clin. Cancer Res. 23, 3297\u20133306 (2017).","journal-title":"Clin. Cancer Res."},{"key":"32960_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00371-6","volume":"10","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. A retrospective comparison of CD19 single and CD19\/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia. Blood Cancer J. 10, 105 (2020).","journal-title":"Blood Cancer J."},{"key":"32960_CR51","doi-asserted-by":"publisher","first-page":"e2584","DOI":"10.7717\/peerj.2584","volume":"4","author":"T Rognes","year":"2016","unstructured":"Rognes, T., Flouri, T., Nichols, B., Quince, C. & Mahe, F. VSEARCH: a versatile open source tool for metagenomics. PeerJ 4, e2584 (2016).","journal-title":"PeerJ"},{"key":"32960_CR52","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s41587-019-0209-9","volume":"37","author":"E Bolyen","year":"2019","unstructured":"Bolyen, E. et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 37, 852\u2013857 (2019).","journal-title":"Nat. Biotechnol."},{"key":"32960_CR53","doi-asserted-by":"crossref","unstructured":"Amir, A. et al. Deblur rapidly resolves single-nucleotide community sequence patterns. Msystems 2, e00191-16 (2017).","DOI":"10.1128\/mSystems.00191-16"},{"key":"32960_CR54","doi-asserted-by":"publisher","first-page":"e9490","DOI":"10.1371\/journal.pone.0009490","volume":"5","author":"MN Price","year":"2010","unstructured":"Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2-approximately maximum-likelihood trees for large alignments. PLoS ONE 5, e9490 (2010).","journal-title":"PLoS ONE"},{"key":"32960_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-018-0470-z","volume":"6","author":"NA Bokulich","year":"2018","unstructured":"Bokulich, N. A. et al. Optimizing taxonomic classification of marker-gene amplicon sequences with QIIME 2\u2019s q2-feature-classifier plugin. Microbiome 6, 90 (2018).","journal-title":"Microbiome"},{"key":"32960_CR56","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","volume":"38","author":"GM Douglas","year":"2020","unstructured":"Douglas, G. M. et al. PICRUSt2 for prediction of metagenome functions. Nat. Biotechnol. 38, 685\u2013688 (2020).","journal-title":"Nat. Biotechnol."},{"key":"32960_CR57","doi-asserted-by":"crossref","unstructured":"Bokulich, N. A. et al. q2-longitudinal: longitudinal and paired-sample analyses of microbiome data. mSystems 3, e00219-18 (2018).","DOI":"10.1128\/mSystems.00219-18"},{"key":"32960_CR58","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1093\/bioinformatics\/btu333","volume":"30","author":"MJ Nueda","year":"2014","unstructured":"Nueda, M. J., Tarazona, S. & Conesa, A. Next maSigPro: updating maSigPro bioconductor package for RNA-seq time series. Bioinformatics 30, 2598\u20132602 (2014).","journal-title":"Bioinformatics"},{"key":"32960_CR59","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1093\/bioinformatics\/btl056","volume":"22","author":"A Conesa","year":"2006","unstructured":"Conesa, A., Nueda, M. J., Ferrer, A. & Talon, M. maSigPro: a method to identify significantly differential expression profiles in time-course microarray experiments. Bioinformatics 22, 1096\u20131102 (2006).","journal-title":"Bioinformatics"},{"key":"32960_CR60","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."}],"updated-by":[{"DOI":"10.1038\/s41467-024-47038-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T00:00:00Z","timestamp":1711497600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32960-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32960-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T04:06:19Z","timestamp":1711598779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32960-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32960"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32960-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-725566\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"16 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-024-47038-5","URL":"https:\/\/doi.org\/10.1038\/s41467-024-47038-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5313"}}